logo
AI founder exposes Indian techie for ‘preying' on startups: ‘Works at 3-4 firms at same time, 10+ companies will agree'

AI founder exposes Indian techie for ‘preying' on startups: ‘Works at 3-4 firms at same time, 10+ companies will agree'

Mint12 hours ago
A US-based AI founder has accused an Indian techie of working simultaneously at multiple firms and deceiving them.
Suhail Doshi, co-founder and former CEO of analytics startup Mixpanel, in a social media post publicly named Soham Parekh, accusing him of 'scamming people' by working at three to four startups at the same time.
'PSA: there's a guy named Soham Parekh (in India) who works at 3-4 startups at the same time. He's been preying on YC companies and more. Beware,' he said in the post on X.
Doshi said he fired the person in the first week itself, asking him to 'stop lying'.
'I fired this guy in his first week and told him to stop lying / scamming people. He hasn't stopped a year later. No more excuses,' he wrote.
Doshi, who also founded Playground AI, also shared the resume of Soham Parekh, which shows that the techie has worked at Dynamo AI, Union AI, Synthesia and Alan AI in a number of technological roles. The CV further shows that he did his bachelor's from the University of Mumbai and master's from Georgia Institute of Technology.
But the Playground founder said, 'Probably 90% fake and most links are gone.'
Parekh said that he tried to explain the impact of this but it did not work out.
'I want to also say that I tried to talk sense into this guy, explain the impact, and give him a chance to turn a new leaf because sometimes that's what a person needs. But it clearly didn't work,' he said.
Suhail Doshi's post has drawn mixed opinions from netizens. While some founders backed Doshi, others asked why moonlighting is wrong.
Nicolai Ouporov, co-founder and CEO of Fleet AI, said Parekh works at more than four startups at any given time. 'He has been doing this for years and works at more than 4 startups at any given time.'
'Has to stop,' Doshi replied.
'I was THIS close to hiring him. the craziest part is he actually crushed the interview,' AIVideo co-founder Justin Harvey.
However, some people asked why moonlighting is wrong if Parekh aced interviews and meets deliverables.
'Why do you feel moonlighting is wrong? If he aced the interviews and was the best so you hired him - what's wrong? As long as he meets all deliverables on time with the right attitude,' a person asked.
'Gets nothing done. Made up constant lies. Corroborated by 6+ other companies. The tweet will surface 10+ more - you'll see,' Doshi replied.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Carlyle Group may sell 10% stake in Piramal Pharma via block deals: Report
Carlyle Group may sell 10% stake in Piramal Pharma via block deals: Report

Business Standard

time20 minutes ago

  • Business Standard

Carlyle Group may sell 10% stake in Piramal Pharma via block deals: Report

United States-based private equity firm Carlyle Group is planning to divest up to 10 per cent stake in Piramal Pharma through block deals, Moneycontrol reported on Thursday, citing sources. The sale could amount to ₹2,600-2,700 crore, the report added. Piramal Pharma sold 20 per cent of its stake to Carlyle Group in June 2020, in a deal worth ₹3,523 crore. According to stock exchange data, it held 18 per cent stake in the pharma firm as of March 31, 2025. Financial services firm Motilal Oswal has been roped in to facilitate the block deals, the report added. Piramal Pharma operates a diverse and global pharmaceutical business, providing a broad range of products and services. It includes Piramal Pharma Solutions (PPS), a fully integrated contract development and manufacturing organisation (CDMO); Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. Piramal Pharma Q4 result In the fourth quarter of FY25, Piramal Pharma posted a consolidated revenue from operations of ₹2,754 crore, marking an 8 per cent increase over the ₹2,552 crore recorded in the same quarter last year. The company's EBITDA (earnings before interest, tax, depreciation, and amortisation) also increased by 8 per cent year-on-year to ₹603 crore, up from ₹556 crore. Profit after tax (before exceptional items) came in at ₹154 crore, reflecting a 16 per cent rise compared to ₹132 crore in the corresponding period of the previous financial year. Shares of Piramal Pharma last traded at ₹202.4 apiece on the BSE at the close of the markets on Thursday.

Explained: How Farm Goods Are Holding Up US-India Trade Deal
Explained: How Farm Goods Are Holding Up US-India Trade Deal

NDTV

time22 minutes ago

  • NDTV

Explained: How Farm Goods Are Holding Up US-India Trade Deal

US and India trade negotiators were pushing on Wednesday to finalise a tariff-reducing deal ahead of President Donald Trump's July 9 negotiating deadline, but disagreements over US dairy and agriculture remained unresolved. Why are farm goods imports sensitive in India? Agriculture and its allied areas contribute just 16% to India's $3.9 trillion economy, but sustain nearly half of the country's 1.4 billion population. As farmers remain the most powerful voting bloc, Prime Minister Narendra Modi's government was forced into a rare retreat four years ago when it tried to push through controversial farm laws. The prospect of cheaper imports from the United States threatens to drive down local prices, handing the opposition a fresh opportunity to attack the government. New Delhi has traditionally kept agriculture out of Free Trade Agreements with other nations. Granting market access to the US could force India to extend similar concessions to other trading partners. How do Indian and US farms compare? The average Indian farm comprises just 1.08 hectares, compared to 187 hectares in the United States. In dairy, the average herd size in India is two to three animals per farmer, compared to hundreds in the United States. This difference makes it difficult for small Indian farmers to compete with their US counterparts. Farming in India remains largely unmechanised because small, fragmented land holdings leave little room for large machinery. In many regions, farmers rely on techniques passed down through generations, a sharp contrast to US farms, where cutting-edge equipment and AI-driven technologies have raised productivity. Which products is US lobbying for? Why is India resisting? The United States is pressing India to open its markets to a wide range of American products, including dairy, poultry, corn, soybeans, rice, wheat, ethanol, citrus fruits, almonds, pecans, apples, grapes, canned peaches, chocolates, cookies, and frozen French fries. While India is willing to grant greater access to US dry fruits and apples, it is holding back on allowing imports of corn, soybeans, wheat, and dairy products. India does not allow genetically modified (GM) food crops, while most US corn and soybean production is GM-based. Dairy remains a sensitive issue in India, where cultural and dietary preferences strongly influence food choices. Indian consumers are particularly concerned that cattle in the US are often fed with animal by-products, a practice that conflicts with Indian food habits. Why does India oppose US ethanol for bleeding with gasoline? A key aim of India's Ethanol Blended Petrol (EBP) program is to cut dependence on energy imports by blending domestically-produced ethanol with gasoline. Significant investments by domestic companies mean that India is now close to achieving its ambitious target of blending 20% ethanol. Importing ethanol would undermine those companies. The EBP also helps manage surpluses of rice, sugarcane, and corn by diverting them to ethanol production. Allowing imports of US ethanol would be a serious setback for India's emerging distillery sector.

Amitabh Kant appointed to IndiGo's board as non-executive director
Amitabh Kant appointed to IndiGo's board as non-executive director

Business Standard

time28 minutes ago

  • Business Standard

Amitabh Kant appointed to IndiGo's board as non-executive director

InterGlobe Aviation, the parent company of IndiGo airline, has appointed former bureaucrat Amitabh Kant as a Non-Executive Director on its Board, the airline said in a statement on Thursday. Kant, a retired Indian Administrative Service (IAS) officer of the 1980 Kerala cadre, has held several senior positions in the Indian government. Most recently, he served as India's G20 Sherpa during the country's presidency. He played a key role in drafting the New Delhi Leaders' Declaration in September 2023. Over a four-decade-long career, Kant also served as CEO of NITI Aayog for six years, where he led programs such as the Aspirational Districts Programme and initiatives on mobility and sustainability. He has previously held board positions at the National Highways Authority of India and was a member of the National Statistical Commission. IndiGo said it expects to leverage Kant's experience in public policy, infrastructure development, and international engagement as it expands its global network. The airline is targeting international growth as part of its 2030 strategy. IndiGo is India's largest airline with more than 60 per cent share in the domestic passenger market. Kant said, 'In under two decades, IndiGo has transformed air travel in India. With its scale, efficiency, and international ambition, IndiGo will open up new markets for India and transform airports into global hubs of connectivity and commerce.' Vikram Singh Mehta, Chairman of the Board of Directors at IndiGo, said, 'Mr. Kant's administrative experience and leadership in delivering projects of global scale will benefit IndiGo, especially in its international expansion efforts.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store